Minverva Biosciences Surrenders Some Of Earlier Gains

Minverva Biosciences

shares are trading higher by $6.30 at $9.84 in Thursday's session. The issue bolted to $15 in premarket trading after the announcement that MIN-101 monotherapy for depression meets primary and secondary endpoints before falling back to the $10 area. Off the open, it rallied to $$10.60 before some profit takers came in. The ensuing decline took it down to $8.25, but now is attempting the $10 handle.